Specify a stock or a cryptocurrency in the search bar to get a summary
Bright Minds Biosciences Inc
DRUGBright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York. Address: 19 Vestry Street, New York, NY, United States, 10013
Analytics
WallStreet Target Price
4.87 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures DRUG
Dividend Analytics DRUG
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History DRUG
Stock Valuation DRUG
Financials DRUG
Results | 2019 | Dynamics |